Clinical Trial Update: Zanubrutinib Combined With BEAM for ASCT in Relapsed and Refractory DLBCL [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating zanubrutinib in combination with BEAM conditioning for autologous stem cell transplantation in relapsed or refractory diffuse …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: Ruijin Hospital | Conditions: DLBCL | Phase 2 | Status: NOT_YET_RECRUITING